Day: April 6, 2022

ZUG, Switzerland and VANCOUVER, British Columbia, April 05, 2022 (GLOBE NEWSWIRE) — Hunter Technology Corp. (TSX- V: HOC; OTCQB: HOILF; WKN: A2QEYH, FSE: RWPM, ISIN: CA4457371090) (“Hunter” or the “Company”) announces the departure of its CFO Mr. Eric Luk. The departure comes as the Company finalizes the previously announced closure of its development center in Hong Kong. The Company has commenced a search for a new CFO centrally located in North America or Europe to allow for a more integrated function with management and its present projects. About Hunter Technology Corp. Hunter Technology Corp. is a blockchain marketplace company that has developed proprietary technologies that digitalise and streamline transaction lifecycles for underserved and inefficient markets. With its Hunter Marketplace Solutions (“HMS”) product, the...

Yellow’s Professional Drivers Meet with President Biden, Highlight Careers in Trucking WASHINGTON, April 05, 2022 (GLOBE NEWSWIRE) — Yellow Corporation (NASDAQ: YELL) on Monday congratulated the Biden-Harris Administration on the progress made in the implementation of the “Trucking Action Plan,” which aims to strengthen America’s supply chain by increasing the number of highly skilled professional semi-truck drivers. On Monday, Yellow CEO Darren Hawkins and two of the company’s professional drivers, Alphonso Lewis and Russell Simpson, joined President Joe Biden, Secretary of Transportation Pete Buttigieg, General President of the International Brotherhood of Teamsters Sean O’Brien and trucking industry leaders at the White House. Lewis, a 30-year driver for Yellow, U.S. Army veteran and America’s Road Team Captain, gave President...

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood vessels, the lymphatic system and other tissues2,3   Approval based on real-world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction in the size of PROS lesions and improvement of PROS-related signs and symptomsNovartis to offer robust patient support program that includes assistance to access medication, financial resources for eligible patients and continued educationBasel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric...